These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26438397)

  • 1. Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.
    Bifulco M; Ciaglia E
    Endocrine; 2016 Sep; 53(3):649-50. PubMed ID: 26438397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins for Graves' orbitopathy: a new tool for prevention and treatment?
    Bartalena L; Piantanida E; Tanda ML
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):726-727. PubMed ID: 34592165
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
    Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
    Nilsson A; Tsoumani K; Planck T
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1325-1332. PubMed ID: 33560351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of graves' orbitopathy: early diagnosis of thyroid-associated orbitopathy in Graves' disease.
    Mourits MP
    Orbit; 2008; 27(6):399-400. PubMed ID: 19085291
    [No Abstract]   [Full Text] [Related]  

  • 6. Statins: A New Hope on the Horizon of Graves Orbitopathy?
    Marinò M; Lanzolla G; Marcocci C
    J Clin Endocrinol Metab; 2021 Jun; 106(7):e2819-e2821. PubMed ID: 33735381
    [No Abstract]   [Full Text] [Related]  

  • 7. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Graves' orbitopathy].
    Balázs C
    Orv Hetil; 2006 Jun; 147(22):1011-7. PubMed ID: 16913090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe.
    Rosetti S; Tanda ML; Veronesi G; Masiello E; Premoli P; Gallo D; Cusini C; Donati S; Sabatino J; Ippolito S; Piantanida E; Bartalena L
    J Endocrinol Invest; 2020 Mar; 43(3):381-383. PubMed ID: 31587179
    [No Abstract]   [Full Text] [Related]  

  • 10. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
    Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
    Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.
    Sabini E; Sisti E; Coco B; Leo M; Ionni I; Menconi F; Profilo MA; Mazzi B; Rocchi R; Latrofa F; Vitti P; Brunetto M; Marcocci C; Marinò M
    J Endocrinol Invest; 2016 Nov; 39(11):1323-1327. PubMed ID: 27465669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic.
    Bartalena L; Chiovato L; Marcocci C; Vitti P; Piantanida E; Tanda ML
    J Endocrinol Invest; 2020 Aug; 43(8):1149-1151. PubMed ID: 32441005
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins as potential addition to anti-Graves' ophthalmopathy armamentarium.
    Fallahzadeh MK; Namazi MR; Vakili H; Soveid M
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):397. PubMed ID: 19486587
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between thyroid-associated orbitopathy and Graves' disease by iTRAQ-based quantitative proteomic analysis.
    Kang J; Li Y; Zhao Z; Zhang H
    FEBS Open Bio; 2021 Jul; 11(7):1930-1940. PubMed ID: 33934566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins may increase the risk of liver dysfunction in patients treated with steroids for active graves' orbitopathy.
    Covelli D; Vannucchi G; Campi I; Currò N; D'Ambrosio R; Maggioni M; Gianelli U; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2015 May; 100(5):1731-7. PubMed ID: 25751109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Animal models of Graves' disease and Graves' orbitopathy.
    Nagayama Y; Nakahara M; Abiru N
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.